Discontinuous Schedule of Bevacizumab in Colorectal Cancer Induces Accelerated Tumor Growth and Phenotypic Changes.

In the case of ALDH1 + , CD44 + , CD166 + , CD133 + cells, the tumor CSC levels increased dramatically ( P <.01) with a 57% increase in group D and a highly significant increase of 90% (7.99±5.1 versus 0.67±0.34 cells %; P <.01) for group F ( Figure 5 D ).

also in 132,142 other papers